Completed PHASE2 NCT00072852

Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

Sponsor: Pfizer

Conditions Breast Neoplasms

Interventions Irinotecan

Updated 6 times since 2017 Last updated: Oct 15, 2008 Started: Nov 30, 2003 Primary completion: May 31, 2007 Completion: May 31, 2007

This PHASE2 trial investigates Breast Neoplasms and is currently completed. Pfizer leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alton, United States , Anchorage, United States , Bogotá, Colombia , Boston, United States , Capital Federal, Argentina , Chalmette, United States , Covington, United States , Córdoba, Argentina , Dallas, United States , Detroit, United States and 39 more locations